ME00930B - Progesteron za sprečavanje prevremenog porođaja - Google Patents
Progesteron za sprečavanje prevremenog porođajaInfo
- Publication number
- ME00930B ME00930B MEP-2009-265A MEP26509A ME00930B ME 00930 B ME00930 B ME 00930B ME P26509 A MEP26509 A ME P26509A ME 00930 B ME00930 B ME 00930B
- Authority
- ME
- Montenegro
- Prior art keywords
- progesterone
- drug according
- cervix
- pregnancy
- administration
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract 40
- 229960003387 progesterone Drugs 0.000 title claims abstract 20
- 239000000186 progesterone Substances 0.000 title claims abstract 20
- 208000005107 Premature Birth Diseases 0.000 title claims abstract 3
- 230000002265 prevention Effects 0.000 title 1
- 210000003679 cervix uteri Anatomy 0.000 claims abstract 14
- 230000035935 pregnancy Effects 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 5
- 238000004904 shortening Methods 0.000 claims abstract 5
- 238000011282 treatment Methods 0.000 claims abstract 4
- 238000011321 prophylaxis Methods 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims 26
- 229940079593 drug Drugs 0.000 claims 20
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims 2
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims 2
- 238000012377 drug delivery Methods 0.000 claims 2
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims 2
- 229960004400 levonorgestrel Drugs 0.000 claims 2
- 229940053934 norethindrone Drugs 0.000 claims 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 2
- 230000002028 premature Effects 0.000 claims 2
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims 1
- 150000000319 19-nortestosterones Chemical class 0.000 claims 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960004976 desogestrel Drugs 0.000 claims 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims 1
- 229960004845 drospirenone Drugs 0.000 claims 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims 1
- 229940012028 ethynodiol diacetate Drugs 0.000 claims 1
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims 1
- 229960002941 etonogestrel Drugs 0.000 claims 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims 1
- 229960005352 gestodene Drugs 0.000 claims 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims 1
- -1 linesterol Chemical compound 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 1
- 229960001652 norethindrone acetate Drugs 0.000 claims 1
- 229960000417 norgestimate Drugs 0.000 claims 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000009597 pregnancy test Methods 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 150000003146 progesterones Chemical class 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 229940044959 vaginal cream Drugs 0.000 claims 1
- 239000000522 vaginal cream Substances 0.000 claims 1
- 229940044950 vaginal gel Drugs 0.000 claims 1
- 239000000029 vaginal gel Substances 0.000 claims 1
- 229940120293 vaginal suppository Drugs 0.000 claims 1
- 239000006216 vaginal suppository Substances 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Postupak za lečenje ili prevencjju spontanog prevremenog porođaja kod trudnica i poboljšavanje neonatalnog morbiditeta i smrtnosti. Postupak obuhvata davanje trudnicama efikasne količine progesterna dovoljne da produži trudnoću minimiziranjem skraćivanja ili otvaranja njihovog grlića. Tretman i profilaksa progesteronom trudnica koje imaju simpotme kratkog grlića je klinički dokazano da povećava neonatalno zdravlje.
Claims (29)
1. Lek koji sadrži progesteron za upotrebu u lečenju i sprečavanju početka prevremenih trudova i naknadnog porođaja kod trudnica sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm, gde je progesteron prisutan u količini koja je dovoljna da minimizira skraćenje grlića.
2. Lek prema zahtevu l, koji je u obliku vaginalnog gela, vaginalne supozitorije, vaginalne kreme ili vaginalnog čvrstog doznog oblika.
3. Lek prema zahtevu l, koji je formulisan za davanje intramuskulamo, oralno, rektalno, subkutanozno, vaginalno, intradermalno, lokalno, intranazalno, intraperitonealno, intraartikulamo, intraventrikulamo, intratekalno, intravaginalno ili intravenskim putem.
4. Lek prema bilo kom od prethodnih zahteva, u kojima je progesteron prirodni progesteron ili metabolit progesterona.
5. Lek prema bilo kom od prethodnih zahteva, u kome progesteron obuhvata sintetički progesteron izabran od 17-alfa-hidroksiprogesteron kaproata, medroksiprogesteron acetata, noretindron, noretindron acetata, noretindron etantata, dezogestrela, levonorgestrel, linesterol, etinodiol diacetata, norgestrela, norgestimata, noretinodrela, gestodena, drospirenona, trimegestrona, levodesogestrela, gestodina, nesterona, etonogestrela i derivata 19-nor-testosterona.
6. Lek prema bilo kom od prethodnih zahteva za dnevno davanje.
7. Lek prema bilo kom od prethodnih zahteva, za davanje od oko 18. do 22. nedelje trudnoće do oko 37. nedelje trudnoće.
8. Lek prema zahtevu 6, za davanje u toku perioda od oko 14 do 19 nedelja.
9. Lek prema zahtevu 6, za davanje od oko 16. nedelje trudnoće do oko 37. nedelje trudnoće.
10. Lek prema zahtevu 6, za davanje u toku perioda od oko 21 nedelje.
11. Lek prema zahtevu 6, za davanje od vremena pozitivnog testa trudnoće do oko 37. nedelje trudnoće.
12. Lek prema zahtevu 6, za davanje od oko 2. do 4. nedelje trudnoće.
13. Lek prema zahtevu 6 za davanje u toku 33 do 35 nedelja.
14. Lek prema zahtevu 6 za davanje u zavisnosti od vremena trudnoće na početku tretmana i dana porođaja.
15. Lek prema bilo kom od prethodnih zahteva, koji je formulisan za davanje od oko 45 mg do oko 800 mg progesterona.
16. Lek prema bilo kom od prethodnih zahteva, koji je u obliku ili sadrži sistem za davanje leka koji sadrži progesteron, vodorastvoran i umetženi polimer polikarboksilne kiseline koji bubri u vodi i bar jedno pomoćno sredstvo.
17. Lek prema bilo kom od prethodnih zahteva, gde grlić trudnice ima dužinu veću od oko 1.0 cm.
18. Lek prema bilo kom od prethodnih zatheva, gde grlić trudnice ima dužinu od oko 1.0 cm do oko 3.0 cm.
19. Lek prema bilo kom od prethodnih zahteva, gde grlić trudnice ima dužinu manju ili jednaku oko 3.0 cm.
20. Lek prema bilo kom od prethodnih zahteva, gde progesteron obuhvata i prirodni progesteron i 17-alfa-hidroksiprogesteron.
21. Lek prema bilo kom od prethodnih zahteva, koji je formulisan za davanje doze od oko 90 mg progesterona i gde je progesteron prirodni progesteron.
22. Lek prema bilo kom od prethodnih zahteva, koji je za upotrebu u poboljšanju neonatalnog morbiditeta i smrtnosti kod prevremene novorođenčadi, očekivane ili naknadno rođene, od trudnica sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm.
23. Lek prema bilo kom od prethodnih zahteva, koji je za davanje u kombinaciji sa jednim ili više jedinjenja za lečenje ili profilaksu prevremenog porođaja.
24. Lek prema bilo kom od zahteva l do 22, koji je za davanje u kombinaciji sa kliničkim postupkom za lečenje ili profilasku prevremenog porođaja.
25. Upotreba progesterona u proizvodnji leka za lečenje ili sprečavanje početka trudova i naknadnog prevremenog porođaja kod trudnica sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm, gde je progesteron korišćen u količini koje je dovoljna da minimizira skraćenje grlića.
26. Uređaj za davanje leka koji je konstruisan za umetanje u vaginu, koji sadrži lek prema bilo kom od zahteva l do 22.
27. Uređaj za davanje prema zahtevu 26, pri čemu je uređaj cervikalni prsten, ili uređaj sadrži cervikalni prsten.
28. Postupak za lečenje ili sprečavanje početka prevremenih trudova i naknadnog prevremenog porođaja kod trudnica sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm, koji se sastoji od davanja ženama progesterona u količini dovoljnoj da smanji skraćenje grlića.
29. Postupak poboljšavanja neonatalnog morbiditeta i smrtnosti kod prevremeno rođene odojčadi koji se sastoji od davanja trudnicama sa kratkim grlićem od oko 1.0 cm do oko 3.5 cm progesterona u količni dovoljnoj da smanji ili odloži dalje skraćenje grlića ili produži trudnoću.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88848007P | 2007-02-06 | 2007-02-06 | |
| US97366707P | 2007-09-19 | 2007-09-19 | |
| PCT/GB2008/000397 WO2008096122A2 (en) | 2007-02-06 | 2008-02-05 | Progesterone for the prevention of preterm birth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00930B true ME00930B (me) | 2012-03-20 |
Family
ID=39301249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2009-265A ME00930B (me) | 2007-02-06 | 2008-02-05 | Progesteron za sprečavanje prevremenog porođaja |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8828981B2 (me) |
| EP (1) | EP2117554B1 (me) |
| JP (2) | JP5580601B2 (me) |
| KR (1) | KR101546101B1 (me) |
| AR (1) | AR065179A1 (me) |
| AU (1) | AU2008212724A1 (me) |
| BR (1) | BRPI0807203A2 (me) |
| CA (1) | CA2677354C (me) |
| CL (1) | CL2008000375A1 (me) |
| CO (1) | CO6220941A2 (me) |
| CR (1) | CR10985A (me) |
| ES (1) | ES2596803T3 (me) |
| GE (1) | GEP20135727B (me) |
| IL (1) | IL200272A (me) |
| MA (1) | MA31200B1 (me) |
| ME (1) | ME00930B (me) |
| MX (1) | MX2009008409A (me) |
| MY (1) | MY184866A (me) |
| NZ (1) | NZ579114A (me) |
| PE (1) | PE20081738A1 (me) |
| RU (1) | RU2524617C2 (me) |
| TW (1) | TWI471135B (me) |
| WO (1) | WO2008096122A2 (me) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014220A2 (en) | 2002-08-13 | 2004-02-19 | N-Dia, Inc. | Devices and methods for detecting amniotic fluid in vaginal secretions |
| US8828981B2 (en) * | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| PL2359807T3 (pl) | 2008-02-04 | 2017-12-29 | Ferring B.V. | Monolityczne pierścienie dopochwowe zawierające progesteron oraz metody ich wytwarzania i stosowania |
| EP2334300B1 (en) | 2008-09-24 | 2016-02-17 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Composition and method for treatment of preterm labor |
| GB0905964D0 (en) * | 2009-04-06 | 2009-05-20 | King S College London | Marker |
| US20110152840A1 (en) * | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| EP2544707B1 (en) * | 2010-03-09 | 2018-11-21 | Dignity Health | Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening |
| US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
| WO2012058463A2 (en) * | 2010-10-27 | 2012-05-03 | Dignity Health | Trimegestone (tmg) for treatment of preterm birth |
| US8951996B2 (en) * | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| DE102012009057A1 (de) * | 2012-05-09 | 2013-11-14 | Dr. Arabin GmbH & Co. KG | Rotationspessar mit zusätzlicher Wirkstoffkomponente |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| ES2761575T3 (es) | 2013-01-02 | 2020-05-20 | Qiagen Sciences Llc | Métodos para predecir el tiempo hasta el parto en una mujer embarazada |
| EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9820994B2 (en) | 2014-06-28 | 2017-11-21 | Laboratorios Andromaco S.A. | Cerclage pessary containing progesterone of prolonged, sustained, and continuous release useful for prevention of preterm birth |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| KR101726488B1 (ko) | 2015-02-23 | 2017-04-13 | 이화여자대학교 산학협력단 | 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물 |
| US9844558B1 (en) | 2015-04-30 | 2017-12-19 | Amag Pharmaceuticals, Inc. | Methods of reducing risk of preterm birth |
| AU2016284459B2 (en) | 2015-06-22 | 2021-12-23 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10231979B2 (en) * | 2015-08-07 | 2019-03-19 | Indiana University Research And Technology Corporation | Modulation of inflammation using progesterone metabolites |
| WO2017040243A1 (en) * | 2015-08-28 | 2017-03-09 | Kypha, Inc. | Methods for predicting flare and improving treatment of patients |
| WO2017059070A1 (en) | 2015-09-29 | 2017-04-06 | Amag Pharmaceuticals, Inc. | Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| CA3022693A1 (en) * | 2016-05-16 | 2017-11-23 | Amag Pharmaceuticals, Inc. | Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same |
| US10656164B2 (en) | 2016-12-22 | 2020-05-19 | Qiagen Sciences, Llc | Screening asymptomatic pregnant woman for preterm birth |
| US10935555B2 (en) | 2016-12-22 | 2021-03-02 | Qiagen Sciences, Llc | Determining candidate for induction of labor |
| JP2018140172A (ja) * | 2017-02-28 | 2018-09-13 | 株式会社Ｎｔｔドコモ | データ収集装置及びデータ収集方法 |
| WO2018232289A1 (en) | 2017-06-15 | 2018-12-20 | Wiesman Holdings, LLC | Device for delivery of a solution into a body orifice |
| RU2657772C1 (ru) * | 2017-07-06 | 2018-06-15 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский институт акушерства и гинекологии" Министерства здравоохранения Московской области | Способ профилактики гестационных осложнений у беременных с эпилепсией |
| US20190038637A1 (en) * | 2017-08-05 | 2019-02-07 | Eric Marchewitz | Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II |
| MX2020004421A (es) * | 2017-10-30 | 2020-09-25 | Carmentix Pte Ltd | Biomarcadores de parto prematuro. |
| RU2692932C2 (ru) * | 2017-11-07 | 2019-06-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | БИОКАТАЛИЗАТОР ДЛЯ ПОЛУЧЕНИЯ 11α-АЦЕТОКСИПРОГЕСТЕРОНА |
| USD918388S1 (en) | 2018-06-15 | 2021-05-04 | Wiesman Holdings, LLC | Solution diffusing head |
| JP7301326B2 (ja) * | 2018-10-16 | 2023-07-03 | 公立大学法人横浜市立大学 | 新生児期～小児期発症の脳小血管病又はその保因者の検出方法 |
| US12310934B2 (en) * | 2019-03-20 | 2025-05-27 | The Regents Of The University Of California | Methods of treatment of spontaneous preterm birth |
| MX2021011885A (es) * | 2019-03-29 | 2022-04-18 | Juniper Pharmaceuticals Inc N/K/A Catalent Jnp Inc | Anillos intravaginales segmentados de eva que contienen progesterona. |
| KR102157438B1 (ko) * | 2019-04-16 | 2020-09-21 | 고려대학교 산학협력단 | 조산 진단 방법 및 키트 |
| CN114728013A (zh) * | 2019-09-23 | 2022-07-08 | 斯坦福大学托管董事会 | 延长妊娠以及月经或妊娠的并发症的治疗方法 |
| WO2021068239A1 (zh) | 2019-10-12 | 2021-04-15 | 国家卫生健康委科学技术研究所 | 用于黄体支持的阴道缓释给药系统及其制备方法与应用 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US12369883B2 (en) | 2020-06-19 | 2025-07-29 | Ultrasound AI, Inc. | Artificial intelligence system for determining clinical values through medical imaging |
| US11266376B2 (en) | 2020-06-19 | 2022-03-08 | Ultrasound Ai Inc. | Premature birth prediction |
| KR102482468B1 (ko) * | 2020-08-11 | 2022-12-28 | 연세대학교 산학협력단 | 조산에 대한 정보 제공 방법 및 이를 적용한 디바이스 |
| US20220072008A1 (en) * | 2020-09-08 | 2022-03-10 | Cedars-Sinai Medical Center | Method of using progesterone receptor agonists for the treatment of covid-19 |
| US12426782B2 (en) | 2020-11-06 | 2025-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and temporal alignment methods for evaluation of gestational age and time to delivery |
| WO2022173786A1 (en) * | 2021-02-10 | 2022-08-18 | Mirvie, Inc. | Methods and systems for conducting pregnancy-related clinical trials |
| KR102823321B1 (ko) * | 2022-01-17 | 2025-06-19 | 연세대학교 산학협력단 | 자궁 경부에 대한 정보 제공 방법 및 이를 이용한 자궁 경부에 대한 정보 제공용 디바이스 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| WO2026072486A1 (en) * | 2024-09-25 | 2026-04-02 | The Population Council, Inc. | Nestorone® for preventing and treating preterm birth |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| DE4229820C2 (de) | 1992-09-07 | 1998-12-03 | Jenapharm Gmbh | Pharmazeutische Zubereitung auf Gestagen-Basis |
| US5830848A (en) | 1992-10-09 | 1998-11-03 | The Regents Of The University Of California | Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy |
| US5948762A (en) | 1993-07-16 | 1999-09-07 | Schering Aktiengesellschaft | Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor |
| US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| CN1151781C (zh) | 1995-03-14 | 2004-06-02 | 舍林股份公司 | 一氧化氮的供体或者一氧化氮的抑制剂调节子宫颈扩张和伸展的用途 |
| US5910482A (en) | 1996-03-19 | 1999-06-08 | Board Of Regents, The University Of Texas System | Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor |
| US6040340A (en) * | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
| US5744463A (en) * | 1996-06-03 | 1998-04-28 | Bair; Glenn O. | Treatment of side effects of progestins and progesterone analogues used for birth control |
| US5985861A (en) | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
| DE69819748T2 (de) | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| US6306914B1 (en) | 1997-10-21 | 2001-10-23 | Columbia Laboratories, Inc. | Progestin therapy for maintaining amenorrhea |
| US20020031513A1 (en) | 1997-11-24 | 2002-03-14 | Shamir Leibovitz | Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
| US5941888A (en) * | 1998-02-18 | 1999-08-24 | Target Therapeutics, Inc. | Vaso-occlusive member assembly with multiple detaching points |
| IL127129A (en) * | 1998-11-18 | 2004-06-01 | Ferring Bv | Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared |
| MXPA02000127A (es) | 1999-06-21 | 2003-01-28 | Columbia Lab Bermuda Ltd | Programacion de ovulacion. |
| US6375970B1 (en) * | 1999-07-07 | 2002-04-23 | Andre Bieniarz | Methods and materials for preterm birth prevention |
| AU2002313517B2 (en) | 2001-08-31 | 2007-09-06 | Bayer Schering Pharma Oy | Drug delivery system |
| FR2832065B1 (fr) * | 2001-11-13 | 2004-11-05 | Besins Int Belgique | Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations |
| FR2842108B1 (fr) | 2002-07-09 | 2008-05-02 | Effik | Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie |
| US20040266025A1 (en) | 2003-02-06 | 2004-12-30 | Durlin Hickok | Screening and treatment methods for prevention of preterm delivery |
| JP2008515909A (ja) | 2004-10-07 | 2008-05-15 | デュラメド ファーマシューティカルズ インコーポレーティッド | 上昇用量延長サイクル療法を利用するホルモン処置の方法 |
| AU2006249349B2 (en) | 2005-05-26 | 2012-01-12 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and methods of making and using the same |
| US8828981B2 (en) | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
-
2008
- 2008-02-01 US US12/024,756 patent/US8828981B2/en active Active
- 2008-02-05 KR KR1020097018528A patent/KR101546101B1/ko not_active Expired - Fee Related
- 2008-02-05 GE GEAP200811451A patent/GEP20135727B/en unknown
- 2008-02-05 AR ARP080100476A patent/AR065179A1/es not_active Application Discontinuation
- 2008-02-05 WO PCT/GB2008/000397 patent/WO2008096122A2/en not_active Ceased
- 2008-02-05 AU AU2008212724A patent/AU2008212724A1/en not_active Abandoned
- 2008-02-05 JP JP2009548733A patent/JP5580601B2/ja not_active Expired - Fee Related
- 2008-02-05 CL CL200800375A patent/CL2008000375A1/es unknown
- 2008-02-05 NZ NZ579114A patent/NZ579114A/en not_active IP Right Cessation
- 2008-02-05 CA CA2677354A patent/CA2677354C/en active Active
- 2008-02-05 MX MX2009008409A patent/MX2009008409A/es unknown
- 2008-02-05 MY MYPI20093240A patent/MY184866A/en unknown
- 2008-02-05 RU RU2009133315/15A patent/RU2524617C2/ru active
- 2008-02-05 ES ES08702057.4T patent/ES2596803T3/es active Active
- 2008-02-05 PE PE2008000250A patent/PE20081738A1/es not_active Application Discontinuation
- 2008-02-05 EP EP08702057.4A patent/EP2117554B1/en not_active Revoked
- 2008-02-05 ME MEP-2009-265A patent/ME00930B/me unknown
- 2008-02-05 BR BRPI0807203-5A patent/BRPI0807203A2/pt not_active Application Discontinuation
- 2008-02-12 TW TW97104900A patent/TWI471135B/zh not_active IP Right Cessation
-
2009
- 2009-07-06 US US12/497,879 patent/US7884093B2/en not_active Expired - Fee Related
- 2009-08-06 IL IL200272A patent/IL200272A/en active IP Right Grant
- 2009-08-21 CR CR10985A patent/CR10985A/es unknown
- 2009-08-31 MA MA32186A patent/MA31200B1/fr unknown
- 2009-09-04 CO CO09094473A patent/CO6220941A2/es not_active Application Discontinuation
-
2013
- 2013-10-25 JP JP2013221869A patent/JP2014058529A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00930B (me) | Progesteron za sprečavanje prevremenog porođaja | |
| CA2256977C (en) | Methods of extended use oral contraception | |
| CA2789238C (en) | Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening | |
| TWI549681B (zh) | 包含助孕素之單石陰道內環及其製造及使用方法 | |
| KR20060126671A (ko) | 에스트로겐 및 프로게스틴을 포함하는 연장 사용 조합제 | |
| HUT51899A (en) | Contraception system and process | |
| US20050101579A1 (en) | Endometriosis treatment protocol | |
| EP3106167A1 (en) | Method for on-demand contraception | |
| ZA200404249B (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | |
| Hammad et al. | An overview of contraception in women with obesity | |
| Meckstroth et al. | Prostaglandins for first-trimester termination | |
| US20030018018A1 (en) | Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea | |
| Pongsatha et al. | Intravaginal misoprostol for pregnancy termination | |
| Bjørge et al. | Early pregnancy termination with mifepristone and misoprostol in Norway | |
| Segal et al. | Breast-feeding and contraception | |
| Depypere et al. | A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause | |
| CN101583364A (zh) | 减轻子宫内膜异位的药物制剂 | |
| McDaniel et al. | Return of menstruation and fertility in Thai women after contraceptive injections | |
| Amrutha | Comparative study of efficacy and safety of Mifepristone and Foley’s catheter in induction of labour | |
| Sandstrøm et al. | Interruption of early pregnancy with mifepristone in combination with gemeprost | |
| Mandlekar et al. | 36.1 TERMINATION OF EARLY PREGNANCY BY MEDICAL METHODS | |
| Corriere Jr et al. | Bacteriuria in young women Effect of estrogen, progestogen, and estrogen-progestogen combination | |
| Ma et al. | POSTCOITAL BLEEDING 60 | |
| Dhont | Non-contraceptive benefits of oral contraceptives | |
| Philips | Migraine and the Pill |